Evidence map›Paper›PMID 11254557›Full record

ArticleInfection and immunity2001

Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.

S Yang, R Tamai, S Akashi, O Takeuchi, S Akira, S Sugawara, H Takada

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 206 citations in OpenAlex.

  1. Article
  2. Article
  3. Muramyl dipeptide potentiatesFrontiers in immunology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Differential Monocyte Actuation in a Three-Organ Functional Innate Immune System-on-a-Chip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Article
  10. Article
  11. Review
  12. AnBioscience of microbiota, food and health · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Therapeutic targeting of NOD1 receptors.British journal of pharmacology · 2013
    Review
  17. Macrophages in tuberculosis: friend or foe.Seminars in immunopathology · 2013
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

S YangDepartment of Microbiology and Immunology, Tohoku University School of Dentistry, Aoba-ku, Sendai 980-8575, Japan.
R Tamai
S Akashi
O Takeuchi
S Akira
S Sugawara
H Takada
Tohoku University · JPOsaka University · JPSaga Medical School Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An analog of 1alpha,25-dihydroxyvitamin D3, 22-oxyacalcitriol (OCT), differentiated human monocytic THP-1 and U937 cells to express membrane CD14 and rendered the cells responsive to bacterial cell surface components. Both THP-1 and U937 cells expressed Toll-like receptor 4 (TLR4) on the cell surface and TLR4 mRNA in the cells, irrespective of OCT treatment. In contrast, OCT-treated U937 cells scarcely expressed TLR2 mRNA, while OCT-treated THP-1 cells expressed this transcript. Muramyldipeptide (MDP) by itself exhibited only a weak ability to induce secretion of inflammatory cytokines such as interleukin-8 (IL-8) in the OCT-differentiated THP-1 cells but showed marked synergistic effects with Salmonella lipopolysaccharide (LPS) or lipoteichoic acid (LTA) from Staphylococcus aureus, both of which exhibited strong activities. Combinatory stimulation with LPS plus LTA did not show a synergistic effect on OCT-differentiated THP-1 cells. Similar results were observed in OCT-differentiated U937 cells, although combination experiments were carried out only with MDP plus LPS. Anti-CD14 monoclonal antibody (MAb) MY4, anti-TLR4 MAb HTA125, and the synthetic lipid A precursor LA-14-PP almost completely inhibited the IL-8-inducing activities of LTA as well as LPS on OCT-treated THP-1 cells, but these treatments increased MDP activity. OCT-treated THP-1 cells primed with MDP exhibited enhanced production of IL-8 upon stimulation with LPS, while the cells primed with LPS showed no change in production upon stimulation with MDP. MDP up-regulated mRNA expression of an adapter molecule to TLRs, MyD88, to an extent similar to that for LPS in OCT-treated THP-1 cells. These findings suggested that LTA as well as LPS activated human monocytic cells in a CD14- and TLR4-dependent manner, whereas MDP exhibited activity in a CD14-, TLR4-, and probably TLR2-independent manner and exhibited synergistic and priming effects on the cells for cytokine production in response to various bacterial components.

Indexed as

Drosophila ProteinsReceptors, ImmunologicAcetylmuramyl-Alanyl-IsoglutamineAdaptor Proteins, Signal TransducingAntigens, DifferentiationCells, CulturedCytokinesDrug SynergismHumansInterleukin-8Lipopolysaccharide ReceptorsLipopolysaccharidesMembrane GlycoproteinsMonocytesMyeloid Differentiation Factor 88Receptors, Cell SurfaceAcetylmuramyl-Alanyl-IsoglutamineAdaptor Proteins, Signal TransducingAntigens, DifferentiationCytokinesDrosophila ProteinsInterleukin-8Lipopolysaccharide ReceptorsLipopolysaccharideslipoteichoic acidMembrane GlycoproteinsMYD88 protein, humanMyeloid Differentiation Factor 88Receptors, Cell SurfaceReceptors, ImmunologicRNA, MessengerTeichoic AcidsTLR2 protein, humanTLR4 protein, humanToll-Like Receptor 2Toll-Like Receptor 4Toll-Like Receptors

Identifiers

PMID11254557
PMCPMC98129
OpenAlexW2114243917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.